{
    "2021-01-21": [
        [
            {
                "time": "2021-01-21",
                "original_text": "Coronavirus update: Biden signs more COVID-19 orders; Pfizer wants to expand sales to states",
                "features": {
                    "keywords": [
                        "Biden",
                        "COVID-19",
                        "Pfizer",
                        "expand",
                        "sales",
                        "states"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-01-25",
                "original_text": "Eli Lilly's Antibody Reduces COVID-19 Risk by 80% in Nursing Homes",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Antibody",
                        "COVID-19",
                        "Risk",
                        "Nursing Homes"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-01-26",
                "original_text": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 per cent for residents",
                "features": {
                    "keywords": [
                        "Lilly",
                        "neutralizing",
                        "antibody",
                        "bamlanivimab",
                        "BLAZE-2",
                        "trial",
                        "residents"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-01-28",
                "original_text": "Jim Cramer on Amazon, Eli Lilly, FuelCell, Vaccines, Stock Market Thursday",
                "features": {
                    "keywords": [
                        "Jim Cramer",
                        "Amazon",
                        "Eli Lilly",
                        "FuelCell",
                        "Vaccines",
                        "Stock Market"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "healthcare",
                        "energy"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-29",
                "original_text": "LIVE: Jim Cramer on Amazon, Eli Lilly, FuelCell, FAANG, Stock Market Thursday",
                "features": {
                    "keywords": [
                        "Jim Cramer",
                        "Amazon",
                        "Eli Lilly",
                        "FuelCell",
                        "FAANG",
                        "Stock Market"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "healthcare",
                        "energy"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "Eli Lilly Says Covid-19 Treatment Reduces Risk for Nursing Home Residents",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Covid-19",
                        "Treatment",
                        "Reduces",
                        "Risk",
                        "Nursing Home Residents"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-02",
                "original_text": "Eli Lilly Says Its Antibody Prevented Covid-19 in Nursing Home Residents",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Antibody",
                        "Prevented",
                        "Covid-19",
                        "Nursing Home Residents"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-03",
                "original_text": "Lilly says antibody drug cuts COVID-19 risk for nursing home residents",
                "features": {
                    "keywords": [
                        "Lilly",
                        "antibody",
                        "drug",
                        "cuts",
                        "COVID-19",
                        "risk",
                        "nursing home residents"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-04",
                "original_text": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents",
                "features": {
                    "keywords": [
                        "Lilly",
                        "neutralizing",
                        "antibody",
                        "bamlanivimab",
                        "BLAZE-2",
                        "trial",
                        "residents"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}